Xi Chuang, Zhang Guo-Qiang, Song Hong-Jun, Shen Chen-Tian, Hou Li-Ying, Qiu Zhong-Ling, Luo Quan-Yong
Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai 200233, China.
Int J Endocrinol. 2022 Mar 10;2022:7173919. doi: 10.1155/2022/7173919. eCollection 2022.
Antithyroglobulin antibodies (TgAbs) could be used as a surrogate tumor marker of TgAb-positive-differentiated thyroid carcinoma. This study aims to determine whether the change in TgAb levels over time could be used as a predictor of responses to therapy in pediatric papillary thyroid carcinoma (PTC) patients.
We retrospectively analyzed the records of 48 pediatric PTC patients with TgAb levels ≥50 IU/ml 6 months after initial I treatment. Suppressed thyroglobulin (Tg) levels 6 months after initial I treatment were used to divide the patients into positive Tg (P-Tg, Tg ≥ 0.2 ng/ml) and negative Tg (N-Tg, Tg < 0.2 ng/ml) groups. Responses to therapy were classified as the acceptable response (AR) group and the not acceptable response (NAR) group.
Of 48 enrolled patients with 58 months (range, 24-143 months) of follow-up, 28 patients had NAR and 20 patients had AR. TgAb levels were decreasing ≥50% in 28 patients, decreasing <50% in 8 patients, and increasing in 12 patients. Multivariate analysis showed that high initial risk stratification and TgAb levels decreasing <50% or increasing were significantly associated with NAR ( < 0.05). Changes in Tg levels were also associated with NAR in the P-Tg group ( < 0.05).
Changes in TgAb levels over time could be used as a predictor of responses to therapy in TgAb-positive pediatric PTC patients. Changes in Tg levels over time are also associated with NAR to therapy in both TgAb-positive and Tg-positive pediatric PTC patients.
抗甲状腺球蛋白抗体（TgAb）可作为TgAb阳性分化型甲状腺癌的替代肿瘤标志物。本研究旨在确定TgAb水平随时间的变化是否可作为儿童乳头状甲状腺癌（PTC）患者治疗反应的预测指标。
我们回顾性分析了48例初始碘治疗6个月后TgAb水平≥50 IU/ml的儿童PTC患者的记录。初始碘治疗6个月后甲状腺球蛋白（Tg）水平被抑制用于将患者分为Tg阳性（P-Tg，Tg≥0.2 ng/ml）和Tg阴性（N-Tg，Tg<0.2 ng/ml）组。治疗反应分为可接受反应（AR）组和不可接受反应（NAR）组。
在48例纳入研究且随访58个月（范围24 - 143个月）的患者中，28例患者有NAR，20例患者有AR。28例患者的TgAb水平下降≥50%，8例患者下降<50%，12例患者上升。多因素分析显示，高初始风险分层以及TgAb水平下降<50%或上升与NAR显著相关（<0.05）。在P-Tg组中，Tg水平的变化也与NAR相关（<0.05）。
TgAb水平随时间的变化可作为TgAb阳性儿童PTC患者治疗反应的预测指标。Tg水平随时间的变化在TgAb阳性和Tg阳性儿童PTC患者中也与治疗的NAR相关。
